XFOR (X4 Pharmaceuticals) ROE % Adjusted to Book Value: -19.76% (As of Mar. 2026)


XFOR X4 Pharmaceuticals Inc XFOR
29 GF Score
Price $3.97
! 7 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals ROE % Adjusted to Book Value?

X4 Pharmaceuticals XFOR -2.93% 29 ROE % Adjusted to Book Value is -19.76% as of Mar. 2026. GuruFocus rates XFOR with a GF Score™ of 29/100. The stock has 7 warning signs investors should review.

X4 Pharmaceuticals's ROE % for the quarter that ended in Mar. 2026 was -45.65%. X4 Pharmaceuticals's PB Ratio for the quarter that ended in Mar. 2026 was 2.31. X4 Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -19.76%.

X4 Pharmaceuticals ROE % Adjusted to Book Value Related Terms

X4 Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for X4 Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

X4 Pharmaceuticals ROE % Adjusted to Book Value Chart

X4 Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -129.28 -83.18 -58.79 -18.07 -38.97

X4 Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.79 -200.81 -259.75 -39.59 -19.76

XFOR vs ZURA, LYEL, LXEO: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, X4 Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

X4 Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's ROE % Adjusted to Book Value falls into.


XFOR
29GF Score
X4 Pharmaceuticals Inc XFOR
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

X4 Pharmaceuticals ROE % Adjusted to Book Value Calculation

X4 Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-75.99% / 1.95
=-38.97%

X4 Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-45.65% / 2.31
=-19.76%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -19.76% mean?
X4 Pharmaceuticals (XFOR) has a ROE % Adjusted to Book Value of -19.76% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on X4 Pharmaceuticals and its competitors.
Is X4 Pharmaceuticals' ROE % Adjusted to Book Value too high?
X4 Pharmaceuticals' current ROE % Adjusted to Book Value is -19.76%. Overall, X4 Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' ROE % Adjusted to Book Value compare to ZURA and LYEL?
X4 Pharmaceuticals' ROE % Adjusted to Book Value of -19.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on X4 Pharmaceuticals and its competitors. X4 Pharmaceuticals's current ROE % Adjusted to Book Value is -19.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current ROE % Adjusted to Book Value of -19.76%. The current ROE % Adjusted to Book Value is -19.76%. X4 Pharmaceuticals' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current ROE % Adjusted to Book Value is -19.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
29GF Score

Get the complete analysis for XFOR

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.97
Price